Improvisation in times of pandemic, a reason for reflection

被引:4
作者
Troya, Jesus [1 ]
Seijo, Luis Miguel [2 ]
Perez, Mario [3 ]
Sentchordi-Montane, Lucia [3 ]
Martinez-Alcala, Alvaro [4 ]
机构
[1] Infanta Leonor Univ Hosp, Dept Internal Med, Madrid, Spain
[2] Clin Univ Navarra, Dept Pulm Dis, Madrid, Spain
[3] Infanta Leonor Univ Hosp, Dept Pediat, Madrid, Spain
[4] Infanta Leonor Univ Hosp, Dept Digest Dis, Madrid, Spain
关键词
D O I
10.1016/j.ijid.2020.05.038
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:361 / 362
页数:2
相关论文
共 7 条
[1]  
[Anonymous], 2020, EACS BHIVA STATEMENT
[2]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMc2008043, 10.1056/NEJMoa2001282]
[3]   In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J].
Chen, F ;
Chan, KH ;
Jiang, Y ;
Kao, RYT ;
Lu, HT ;
Fan, KW ;
Cheng, VCC ;
Tsui, WHW ;
Hung, IFN ;
Lee, TSW ;
Guan, Y ;
Peiris, JSM ;
Yuen, KY .
JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) :69-75
[4]   Estimating the reproductive number and the outbreak size of COVID-19 in Korea [J].
Choi, Sunhwa ;
Ki, Moran .
EPIDEMIOLOGY AND HEALTH, 2020, 42
[5]  
Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]
[6]  
Malaysian Society of Infectious Diseases Chemotherapy, 2020, Guidelines for Adult Immunization, V3rd ed.
[7]   No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection [J].
Molina, J. M. ;
Delaugerre, C. ;
Le Goff, J. ;
Mela-Lima, B. ;
Ponscarme, D. ;
Goldwirt, L. ;
de Castro, N. .
MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (04) :384-384